The cannabis industry has been notoriously booming for some time now, but with larger and larger competition occurring in the space, it seems that now is more the time than ever to get involved. Most investors have been watching the larger cap companies in the cannabis space, but there is a myriad of small cap companies with a large amount to offer in the way of innovation and new products.
The company Delta 9 (TSXV:NINE) is a Canadian based producer of medicinal cannabis. The company has been working on the production of over 20 various strains for sale throughout the cannabis industry domestically. According to one report “ Delta 9 reached a licensing agreement with Nanosphere Health Sciences (CSE:NSHS), which granted Delta 9 a license to use Nanosphere’s patented delivery system technology in Canada. The technology utilizes nanoparticles to deliver cannabis into the circulatory system and relieving pain, anxiety, and inflammation. As per the agreement, Delta 9 is permitted to subcontract the patent to other providers in Canada.” The hopes are that this new and innovative technology will help to continue fueling growth within the cannabis space. With a 1 month return of around 46% and a year on year return at over ten times that, it seems as though this is one company to keep on any investors watch.
The company RavenQuest Biomed (CSE: RQB) is another cannabis company that has been working to up their production of the cannabis plant. With several facilities that in total have been able to produce as much as 11,000 kg/year of cannabis, the company is still working to up their production by a large amount. The company has been working with the McGill University in Montreal to learn how they can up the yields of their cannabis growing operations, and this should help them in the short term.
The company GT Biopharma Inc (GTBP) has been one of the big players in the cannabis space regarding biotech for some time now, and has been working on creating new and innovative drugs to help patients with a myriad of ailments. GT Biopharma has been stated to have the perfect amount of exposure to the growth potential of the cannabis market, while still offering a large amount of stability given their scientific approach and the fact that they are not a grower of cannabis in the space. GT Biopharma looks like it should stay on any investors watch list.
The cannabis industry as a whole has continued to grow for a long time now, but this only looks as though it is the beginning. The hopes are high that over the course of the coming months to years, the cannabis market will remain at the forefront of the fastest growing spaces to invest in.
Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC, Midam Ventures LLC and GT Biopharma, Midam has been paid $200,000 from the company and ZERO shares of GT Biopharma Inc. for a duration beginning July 16, 2018 and ending August 16, 2018. Midam Ventures has been paid an additional $200k by GT Biopharma and has extended its marketing period through Sept 16, 2018. We may buy or sell additional shares of (GTBP) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
